[ad_1]
Dublin, 31 May 2019 (GLOBE NEWSWIRE) – The report "Technologies enabling the development of a new generation vaccine" has been added to ResearchAndMarkets.com & # 39; s offer.
Vaccine distribution platforms: This section covers various nanoparticle-based vaccine delivery platforms, such as nanoparticles of biological origin (self-badembling proteins) and non-biological (inorganic and polymeric). The biological nanoparticle subsection overlaps with viral-like particles that have been treated separately.
Pseudo-viral particles: The virus-like particles are biological nanoparticles of a size of about 20 to 100 nm. Because of their repetitive nature, viral capsid proteins tend to self-bademble. The lack of genetic material makes these vaccines non-replicative and therefore safe vaccines. As a result, VLPs attract a lot of appeal from the point of view of vaccine development.
Bacterial and fungal vaccines: This section deals with future vaccines that can protect against multiple bacterial and fungal infections, antitoxoid vaccines, neutralizing antibodies and new technologies such as conjugated carbohydrate vaccines, surface antigens, etc.
Synthetic vaccines: The segment of synthetic vaccines speaks of short, long and synthetic peptide vaccines against viral and bacterial diseases, novel T-cell stimulating immunogens and fusion proteins.
Vaccines with viral vectors: It covers genetically engineered viral vectors designed to render replication incompetent by the removal of essential genes or highly attenuated viral vectors lacking pathogenic genes.
Adjuvant technology: Here we present unique lipid-based adjuvants, oil-in-water adjuvants, plant-derived adjuvants, synthetic adjuvants and immune receptors as well as virosomes (derived from viral proteins).
Platforms for synthesis, formulation and administration of vaccines: This section partially overlaps with the delivery platforms for virus-based vaccines such as virosomes, synthetic and modified viral platforms, cell-free protein synthesis, gene delivery methods, and proprietary cell lines. for the production of vaccines.
Key topics covered:
1.0 Summary
1.1 Scope of research: vaccine technologies in the development phase
1.2 Framework for Analysis: Fundamental Value of Frost & Sullivan
1.3 Research Methodology: Five Steps to Success
1.4 Key findings of the global development of vaccine technology
2.0 Technological Snapshot
2.1 Scope of Research: Current Status and Challenges of Vaccine Development
2.2 Technologies transforming new generation vaccines
3.0 Nanoparticles as New Platforms for Vaccine Delivery
3.1 Nanoparticles enable efficient and safe vaccine delivery
3.2 Nanoparticles of self-badembly of biological origin
3.3 Polymeric and inorganic nanoparticles for the administration of vaccines
4.0 Virus-like particles are self-badembling proteins of the capsid of the virus without genetic material
4.1 Virus-like particles mimic the actual viral infection
4.2 Landscape of VLP Vaccines, Global, 2019
4.3 Influenza A significant part of VLP vaccines
4.4 Multiple Adaptations of VLP Technology for Vaccine Development
4.5 Plant Leaves producing a wide variety of VLPs
5.0 Bacterial and fungal vaccines
5.1 New technologies for bacterial and fungal vaccines
5.2 Emerging Bacterial and Fungal Vaccines, Global, 2019
5.3 New strategies for bacterial and fungal vaccines
5.4 New vaccines and new treatments for emerging infectious diseases
5.5 Bacterial Vaccines Based on Multiprotein Complexes
5.6 Vaccines based on carbohydrates or conjugates
6. Synthetic vaccines
6.1 State of Development of Synthetic Vaccines, Global, 2019
6.2 Peptide Vaccine Technologies
6.3 Genetically Modified Vaccines against HIV and Streptococci
7.0 Vector-based viral vaccines
7.1 Overview of viral vector vaccines
7.2 Summary of Viral Vector Vaccine Development Technology, Global, 2019
7.3 Various viral vaccines incompetent for replication
7.4 Viruses incompetent for replication with nasal spray formulation
7.5 Live attenuated influenza vaccines with nasal formulation
7.6 Vector Viral Vaccines for Serious Human Diseases
8.0 Adjuvant technology
8.1 New lipid formulations as an adjuvant
8.2 Saponin-based additives and oil-in-water nanoemulsion
8.3 Adjuvants based on Toll type receptors
9.0 Platforms for vaccine synthesis, formulation and administration
9.1 Synopsis of Vaccine Synthesis and Platforms for Formulation Administration
9.2 Cell-free and cell-based vaccine synthesis platforms
9.3 Vaccine formulation technologies
9.4 Formulation and Device for Administration of Needle-free Solid Dose Vaccine
9.5 Gold nanoparticles and applications in the administration of vaccines
9.6 Nanopatch Lipid and Recombinant Protein Transporters
10. Opportunities for growth and corporate action
10.1 Opportunity for Growth 1: Influenza Vaccines
10.2 Opportunity for growth 2: Vaccines against viral vector diseases
10.3 Opportunity for Growth 3: Vaccine Delivery Technologies
10.4 Strategic imperatives for success and growth
11. Key influencers of the industry
For more information on this report, visit https://www.researchandmarkets.com/r/n9e8ac.
Research and Markets also offers customized research services that provide targeted, comprehensive and personalized research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Secretary [email protected] For office hours, call 1-917-300-0470 For toll-free calls to the United States and Canada: 1-800-526-8630 For GMT office hours, call + 353-1-416-8900 Related Topics: Vaccines
Source link
